ALZN: financial statements from SEC — TradeAlmanac

ALZN

Alzamend Neuro, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Oct 31, 2025	Jul 31, 2025	Jan 31, 2025	Oct 31, 2024	Jul 31, 2024
Research and development	176,283	2m	447,111	311,088	206,571
Selling, general and administrative	821,826	959,334	590,304	1m	755,834
Operating expenses	998,109	3m	1m	1m	962,405
Operating income	−998,109	−3m	−1m	−1m	−962,405
Interest expense	2,649	2,483	2,019	3,495	12,006
Net income	−1m	−3m	−1m	−1m	−974,411
Earnings per share	−0.30	−1.28	−0.19	−3.61	−11.42
Earnings per share, diluted	−0.30	−1.28	−0.19	−3.61	−11.42
Weighted average shares	3m	2m	6m	392,411	85,314
Weighted average shares, diluted	3m	2m	6m	392,411	85,314

Balance sheet

Metric	Feb 28, 2026	Oct 31, 2025	Jul 31, 2025	Apr 30, 2025	Jan 31, 2025	Oct 31, 2024	Jul 31, 2024	Apr 30, 2024
Cash and equivalents	—	4m	6m	4m	3m	4m	1m	376,048
Current assets	—	5m

Cash flow

Metric	Jul 31, 2025	Jul 31, 2024
Operating cash flow	−2m	−1m
Depreciation and amortisation	27,685	12,685
Share-based compensation	42,902	81,277
Investing cash flow	—	−90,000
Financing cash flow	4m	2m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)